The BAX Knockout 769-P Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 769-P clear cell renal cell carcinoma epithelial cell line. These cells carry a targeted disruption of the BAX gene, generating a loss-of-function model that enables investigation of BAX-dependent apoptotic signaling. The polyclonal nature of the population reflects the heterogeneous editing outcomes inherent to CRISPR/Cas9-mediated gene disruption, providing a robust cellular background for studying apoptosis regulation in a cancer-relevant context without the clonal selection bias associated with single-cell-derived lines.
The host 769-P cell line is a well-established adherent epithelial model originating from a human clear cell renal cell carcinoma. These cells retain key characteristics of kidney epithelial cells, including their morphological features and renal cell carcinoma-associated molecular profiles. As a renal cell carcinoma model, 769-P cells are widely used to explore oncogenic signaling, drug response, and apoptotic regulation. Their epithelial origin and carcinoma background make them particularly relevant for dissecting how tumor cells evade programmed cell death, a hallmark of cancer progression.
BAX is a pivotal pro-apoptotic member of the BCL-2 protein family that functions as an executioner of mitochondrial outer membrane permeabilization. Upon activation by upstream signals??such as p53-mediated transcription, DNA damage, hypoxia, or BH3-only proteins including BIM, PUMA, NOXA, and tBID??BAX undergoes conformational changes, translocates to the mitochondria, and oligomerizes in the outer membrane. This process releases cytochrome c into the cytosol, where it binds APAF1 to form the apoptosome, recruiting and activating caspase-9. Subsequent cleavage of effector caspases, notably caspase-3, and downstream substrates like PARP leads to the biochemical and morphological culmination of intrinsic apoptosis. BAX activity is tightly regulated by interactions with anti-apoptotic BCL-2 family members such as BCL-2, BCL-XL, and MCL-1, which prevent its oligomerization, as well as by direct binding to BH3-only sensitizers and activators.
In the 769-P renal cell carcinoma cell line, BAX expression is frequently intact but apoptosis is often suppressed through overexpression of anti-apoptotic BCL-2 family proteins or defects in upstream stress-sensing pathways. The BAX polyclonal knockout model thus provides a powerful tool for dissecting apoptosis resistance in kidney cancer. By eliminating BAX function, researchers can assess the dependence of intrinsic apoptosis on this effector, evaluate the contributions of parallel pro-apoptotic effectors such as BAK, and interrogate the signaling hierarchy connecting p53, BH3-only proteins, and mitochondrial permeabilization. This model is particularly suited for exploring how renal cell carcinoma cells bypass apoptosis in response to therapeutic agents or metabolic stress.
Typical research applications include quantitative assessment of apoptosis regulation via western blotting for BAX, BCL-2, caspase-3, and cleaved PARP; flow cytometry-based Annexin V and JC-1 mitochondrial membrane potential assays; cytochrome c release assays; and caspase activity measurements. The cells are also valuable for BH3 mimetic drug screening to evaluate therapeutic sensitivity, co-immunoprecipitation analyses of BCL-2 family interactions, and immunofluorescence monitoring of BAX translocation. Studies of mitochondrial dysfunction and cancer cell survival mechanisms are central to this model’s utility. For additional information, please contact Ascent Research.
